JNJ 8-K 2026-07-15
JOHNSON & JOHNSON (JNJ) 8-K dated 2026-07-15 — accession 0000200406-26-000146. This URL is the filing, not the JNJ hub.
JOHNSON & JOHNSON (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
JNJ: Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.
Latest reported JNJ revenue for 2025-12-28 was $94.19B. Net income was $26.80B. Revenue was up 6.0% from 2024-12-29 to 2025-12-28. JNJ currently screens at market cap $375.37B and trailing P/E 40.1.
Not investment advice. The JNJ SEC hub lists recent forms. The stock page is the research view.
- Guidance
- guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13
Why it matters
- guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13